Optinose, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OPTN
Optinose, INC10-K/A: Optinose Files Amendment to 2024 Annual Report Amidst Merger Agreement with Paratek Pharmaceuticals
Optinose files an amendment to its 2024 Annual Report on Form 10-K/A to include Part III information and update certain disclosures, coinciding with a pending merger agreement with Paratek Pharmaceuticals.
OPTN
Optinose, INCOptiNose, Inc. reports its annual results, highlighting XHANCE commercialization efforts and a pending merger with Paratek Pharmaceuticals, while acknowledging substantial doubt about its ability to continue as a going concern.
OPTN
Optinose, INCOptiNose's future is uncertain as it grapples with debt covenants and the need for additional capital, despite positive clinical trial results for its drug XHANCE.